5-Hour Energy: A Success Equal Parts Caffeine, Chemistry and…
Suddenly, Amazon Doesn't Love Its Moms AnymoreUncertain economic times, it goes without saying, create uphill conditions for most stocks. But that does not mean one should not search for promising opportunities, and one that fits the bill, for high-risk investors, is Biomarin Pharmaceutical.
Biomarin Pharmaceutical Inc. (Nasdaq: BMRN) develops and commercializes drugs for rare and chronic diseases.
Analysts like the fact that two of its drugs qualify for FDA orphan drug status, which grants exclusive marketing rights for seven years.
Biomarin's Aldurazyme, the sole therapy for mucopolysaccharidosis I (MPS I), obtained orphan drug status in the U.S. for seven years and in Europe for 10 years. Also, the company's Naglazyme is approved in the U.S. and Europe to treat MPS VI (Maroteaux-Lamy syndrome), another rare, genetic disease. The Reuters FY 2007/FY 2008 EPS consensus estimates for BMRN are -$0.15 to $0.49.
Biomarin Pharmaceutical Inc. (Nasdaq: BMRN) develops and commercializes drugs for rare and chronic diseases.
Analysts like the fact that two of its drugs qualify for FDA orphan drug status, which grants exclusive marketing rights for seven years.
Biomarin's Aldurazyme, the sole therapy for mucopolysaccharidosis I (MPS I), obtained orphan drug status in the U.S. for seven years and in Europe for 10 years. Also, the company's Naglazyme is approved in the U.S. and Europe to treat MPS VI (Maroteaux-Lamy syndrome), another rare, genetic disease. The Reuters FY 2007/FY 2008 EPS consensus estimates for BMRN are -$0.15 to $0.49.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
